ENDV ENDONOVO THERAPEUTICS, INC.
Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 1528172 · Fiscal year ends 12/31
Financial factors as of 2023-09-30 (2023Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,699.9%
TTM net income YoY-40.0%
TTM EPS YoY—
Revenue 3-yr CAGR-5.5%
Net income 3-yr CAGR—
Margins
Gross margin96.2%
Operating margin-1,023.2%
Net margin-1,722.2%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-388.5%
ROIC (approx.)—
Asset turnover0.23x
Leverage & solvency
Liabilities / assets2,914.6%
Debt / equity—
Current ratio0.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.14x
Accruals ratio-333.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $135,355 | $73,105 |
| Cost of revenue | $9,990 | $14,985 |
| Gross profit | $125,365 | $58,120 |
| R&D expense | — | $0 |
| Operating income | -$3.26M | -$2.23M |
| Interest expense | — | $941,566 |
| Pretax income | -$18.47M | -$3.10M |
| Net income | -$18.47M | -$3.10M |
| EBITDA | -$2.62M | -$1.58M |
| EPS (basic) | -0.13 | -0.05 |
| EPS (diluted) | — | -0.05 |
| Weighted avg. shares (diluted) | — | 59.84M |
| Banking | ||
| Net interest income | -$1.32M | -$941,566 |
| Balance sheet | ||
| Cash & equivalents | $98 | $85,936 |
| Receivables | — | $944 |
| Current assets | $15,822 | $94,855 |
| Intangibles | $1.27M | $1.91M |
| Total assets | $1.28M | $2.01M |
| Current liabilities | $33.38M | $17.70M |
| Long-term debt | $7.15M | $7.26M |
| Total debt | $7.15M | $7.26M |
| Total liabilities | $33.46M | $17.78M |
| Shareholders' equity | -$32.18M | -$15.77M |
| Net debt | $7.15M | $7.17M |
| Shares outstanding | 213.23M | 74.50M |
| Cash flow statement | ||
| Operating cash flow | -$678,838 | -$986,584 |
| Financing cash flow | $593,000 | $1.06M |
| Depreciation & amortization | $646,912 | $648,492 |
| Stock-based compensation | $45,000 | $0 |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.